• Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • Pan-Amyloid Removal (PAR)
    • Pan-Amyloid Diagnostic
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
    • In the News
  • Amyloidosis
  • Careers
  • Contact
Attralus Inc. logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • Pan-Amyloid Removal (PAR)
    • Pan-Amyloid Diagnostic
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
    • In the News
  • Amyloidosis
  • Careers
  • Contact
Infographic – Systemic Amyloidosis Everything You Need to Know

Infographic – Systemic Amyloidosis Everything You Need to Know

Mar 1, 2022

Recent Posts

  • Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session
  • Fully Automated 3D Segmentation and Quantitation of the Amyloidophilic Radiotracer Iodine Evuzamitide (124i-P5+14, AT-01) in the Heart of Patients with Systemic Amyloidosis and Healthy Subjects
  • Detection of Cardiac Amyloidosis in Patients with Systemic AL and ATTR Amyloidosis Using Iodine Evuzamitide PET/CT Imaging and the Correlation with Serum NT-proBNP
  • Attralus Appoints James Testa as Vice President of Finance
  • Attralus is Developing a New Treatment for Systemic Amyloidosis

Recent Comments

No comments to show.
COMPANY
About
Management Team
Board of Directors
Scientific Advisory Board
Investors
SCIENCE

Approach
Pan-Amyloid Removal (PAR)
Pan-Amyloid Diagnostic

PIPELINE

 

NEWS

Press Releases
Posters & Publications
In the News

HOME
AMYLOIDOSIS
CAREERS
CONTACT
  • Privacy Policy
  • Terms of Service
  • Follow
  • Follow

Attralus, Inc.
‍
50 Francisco Street
Suite 450
San Francisco, CA 94133

©2022 Attralus, Inc.  All Rights Reserved.